Anticoagulant therapy in the management of patients with atrial fibrillation from the viewpoint of comorbidities: focus on choice

Abstract

The article discusses the choice of anticoagulant therapy in patients with atrial fibrillation and a number of concomitant diseases – coronary heart disease, including after percutaneous coronary interventions, diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease, and in the elderly. The data of subanalyses of a randomized clinical trial of ARISTOTLE are presented, indicating a high profile of efficacy and safety of the new oral anticoagulant apixaban in this category of patients.

Keywords

• atrial fibrillation
• ischemic heart disease
• diabetes mellitus
• chronic kidney disease
• multimorbidity
• advanced age
• anticoagulant therapy
• apixaban